Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of “Buy” from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, MarketBeat reports. Eleven investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $69.56.

Several analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research report on Wednesday, May 15th. Evercore ISI assumed coverage on shares of Jasper Therapeutics in a research report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Jasper Therapeutics in a research report on Thursday, June 27th. They issued a “buy” rating and a $86.00 price objective on the stock. TD Cowen assumed coverage on shares of Jasper Therapeutics in a research report on Monday, March 18th. They issued an “outperform” rating on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of JSPR. Opaleye Management Inc. purchased a new stake in Jasper Therapeutics during the fourth quarter valued at approximately $3,144,000. Kingdon Capital Management L.L.C. lifted its position in Jasper Therapeutics by 16.4% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after acquiring an additional 500,000 shares during the last quarter. Monaco Asset Management SAM purchased a new stake in Jasper Therapeutics during the fourth quarter valued at approximately $197,000. StemPoint Capital LP purchased a new stake in Jasper Therapeutics during the first quarter valued at approximately $3,794,000. Finally, Ikarian Capital LLC purchased a new stake in Jasper Therapeutics during the first quarter valued at approximately $3,088,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Down 4.7 %

Shares of JSPR stock opened at $19.10 on Wednesday. The stock has a market cap of $287.65 million, a P/E ratio of -3.39 and a beta of 2.21. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01. The company’s fifty day simple moving average is $22.85 and its two-hundred day simple moving average is $20.66.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.23. On average, analysts anticipate that Jasper Therapeutics will post -4.41 EPS for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.